PADMANEE SHARMA to Cell Line, Tumor
This is a "connection" page, showing publications PADMANEE SHARMA has written about Cell Line, Tumor.
Connection Strength
0.574
-
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Nat Commun. 2024 Jul 10; 15(1):5291.
Score: 0.081
-
Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
Score: 0.059
-
Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner. Cancer Immunol Res. 2019 Nov; 7(11):1803-1812.
Score: 0.057
-
Characterization and Comparison of GITR Expression in Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6501-6510.
Score: 0.057
-
Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J Clin Invest. 2018 08 31; 128(9):3813-3818.
Score: 0.053
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.049
-
Loss of IFN-? Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016 Oct 06; 167(2):397-404.e9.
Score: 0.047
-
Interdependent IL-7 and IFN-? signalling in T-cell controls tumour eradication by combined a-CTLA-4+a-PD-1 therapy. Nat Commun. 2016 08 08; 7:12335.
Score: 0.046
-
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007 Mar 06; 104(10):3967-72.
Score: 0.024
-
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
Score: 0.016
-
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J Immunother Cancer. 2019 12 16; 7(1):351.
Score: 0.015
-
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018 04 02; 128(4):1338-1354.
Score: 0.013
-
Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018 02; 6(2):189-200.
Score: 0.013
-
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017 02 13; 8:14340.
Score: 0.012
-
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
Score: 0.012
-
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77.
Score: 0.011
-
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.
Score: 0.010